<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1488">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623385</url>
  </required_header>
  <id_info>
    <org_study_id>SARS -2</org_study_id>
    <nct_id>NCT04623385</nct_id>
  </id_info>
  <brief_title>Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?</brief_title>
  <official_title>Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kafrelsheikh University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kafrelsheikh University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Role of Testosterone and Dihydrotestosterone and which of them should be inhibited&#xD;
      in COVID-19 patients - A double-edged sword?&#xD;
&#xD;
      COVID-19 attacks and affects Males significantly more than females [1], [2]. Males with&#xD;
      COVID-19 are reported to die at twice the rate of females when they come infected with the&#xD;
      virus [3]. The upregulation of TMPRSS2 by androgens could explain the increased&#xD;
      susceptibility to COVID-19 in men.Contrary to expected, as a study demonstrated that The&#xD;
      expression level of TMPRSS2 increased 6-fold in androgen stimulated LNCaP cells, relative to&#xD;
      androgen-deprived cells[4]. But, surprisingly, low levels of testosterone led to the over&#xD;
      expression and upregulation of ACE2 and TMPRSS2 receptors, facilitating SARS-CoV-1 entry into&#xD;
      the alveolar cells, and deregulating a lung-protective pathway [5].According to literature&#xD;
      Dihydrotestosterone is many times more potent than testosterone, and many of the effects that&#xD;
      testosterone has in the body only happen after it is converted to dihydrotestosterone [6].&#xD;
      Therefore, we hypothesis that testosterone has better effect than dihydrotestosterone in case&#xD;
      of COVID-19, because a study found that DHT significantly induced the expression of TMPRSS2&#xD;
      [7]. And at the same time , decreased testosterone levels in critically diseased males&#xD;
      harmfully affect pulmonary endothelial cell functioning, impair the ability to clear the&#xD;
      virus , promote systemic . Obesity among males, promote defective immune response, , and also&#xD;
      generates more pro-inflammatory cytokines important in cell signaling, emanating in&#xD;
      increased, severe disease, worst outcome and vulnerability. Insufficient serum testosterone&#xD;
      level is a poor prognostic indicator for patients infected with COVID-19 by downregulation&#xD;
      pulmonary protective pathways [5], [8]. On the contrary, high testosterone levels can lead to&#xD;
      complication of thrombosis which is also one of the serious manifestations in COVID-19&#xD;
      patients[9]. Thereby we hypothesize that decreased testosterone levels in men have a direct&#xD;
      relation with the severity of infection and a worse outcome in COVID-19. In this case we&#xD;
      should found an appropriate treatment that induces testosterone level to introduce its&#xD;
      protective effect and up regulate pulmonary protective pathways and at the same time protect&#xD;
      against thrombosis and works to reduce the impact of dihydrotestosterone on lung cells&#xD;
      preventing up regulation of TMPRSS2, Her we shed new light on the appropriate treatment can&#xD;
      overcome the challenges that face testosterone therapy in the era of COVID-19 After searching&#xD;
      MEDLINE , PubMed, , Google Scholar, preprints and Controlled Trials until September , 2020 we&#xD;
      found that the appropriate treatment in this case is aerosolized 13 cis retinoic acid in&#xD;
      combination with testosterone therapy, as more than one study found that 13 cis retinoic acid&#xD;
      reversibly and potentially inhibit the effect of dihydrotestosterone on different targeted&#xD;
      cells. In addition its impact on thrombin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized interventional comparative Phase IIII trial. 1000 adult male and&#xD;
      female patients with positive COVID-19 diagnosis and fulfilling the below outlined inclusion&#xD;
      criteria will be enrolled into the study.&#xD;
&#xD;
      After searching PubMed, MEDLINE, Google Scholar, preprints and Controlled Trials until&#xD;
      September , 2020 we found that the best and appropriate drug which can be combined with&#xD;
      testosterone replacement therapy is aerosolized 13 cis retinoic acid owing to its impact on&#xD;
      DHT and thrombin in addition it can be given in the form of aerosol for targeting pulmonary&#xD;
      cells with minimal systemic side effects . As previous study found that testosterone therapy&#xD;
      (TTh) administration using both topical and injectable formulations yielded transient and&#xD;
      concomitant rises in both DHT and T, with higher Hct elevations in men with higher DHT and T&#xD;
      levels[38]. As Testosterone is converted to DHT by the action of 5 alpha-reductase enzyme at&#xD;
      these target tissues.[39]. DHT is a potent activator of TMPRSS2[31,4] and this will be&#xD;
      followed by the activation of COVID-2019 spike protein to bind to its ACE2 receptors in lung&#xD;
      which in turn makes it more vulnerable to covid-19. A study demonstrated that 13- cis&#xD;
      -Retinoic acid competitively and reversibly inhibits dihydrotestosterone.[40] on contrary to&#xD;
      other selective inhibitor of serum DHT which led to sexual adverse effects because it usually&#xD;
      given systemically which increases the chance of systemic serious side effects . But 13- cis&#xD;
      -Retinoic acid will be given in the form of aerosol to avoid these systemic side effects.&#xD;
      Therefore, we suggest that 13- cis -Retinoic acid will downregulate TMPRSS2 expression&#xD;
      thorough temporary preventing the effect of dihydrotestosterone (DHT) on the activation of&#xD;
      TMPRSS2 gene expression. Furthermore, 13- cis -Retinoic acid Found to exert potential effect&#xD;
      on thrombin as high testosterone levels can lead to thrombosis which is also one of the fatal&#xD;
      manifestations in COVID-19 patients .A study in vitro found that Retinoic acid showed the&#xD;
      highest inhibition of both the forms of thrombin [41].&#xD;
&#xD;
      Moreover, we hypothesize that any drug which downregulates TMPRSS2 expression through&#xD;
      targeting AR, AR co-regulatory factors, or AR downstream transcription factors might be&#xD;
      potentially effective against COVID-19 and is worth investigating under a clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lung injury score</measure>
    <time_frame>at 7and 14 days</time_frame>
    <description>Proportion of lung injury score decreased or increased after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute lymphocyte counts</measure>
    <time_frame>at 7and 14 days</time_frame>
    <description>lymphocyte counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon</measure>
    <time_frame>at 7and 14 days</time_frame>
    <description>Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of COVID19 RNA</measure>
    <time_frame>at 7and 14 days</time_frame>
    <description>Serum level of COVID19 RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiotensin 1-7 (Ang 1-7) changes over time</measure>
    <time_frame>at 7and 14 days</time_frame>
    <description>Angiotensin 1-7 (Ang 1-7) changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiotensin 1-5 (Ang 1-5) changes over time</measure>
    <time_frame>at 7and 14 days</time_frame>
    <description>Angiotensin 1-5 (Ang 1-5) changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin changes over time</measure>
    <time_frame>at 7and 14 days</time_frame>
    <description>Renin changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone changes over time</measure>
    <time_frame>at day 7 and 14</time_frame>
    <description>Aldosterone changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiotensin-converting enzyme (ACE) changes over time</measure>
    <time_frame>at day 7 and 14</time_frame>
    <description>Angiotensin-converting enzyme (ACE) changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events and severe adverse events</measure>
    <time_frame>at day 7 and 14</time_frame>
    <description>Frequency of adverse events and severe adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transe membrane protease ,serine II (TMPRSS2) changes over time</measure>
    <time_frame>day 7 and 14</time_frame>
    <description>Transe membrane protease ,serine II (TMPRSS2) changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone levels changes over time</measure>
    <time_frame>day 7 and 14</time_frame>
    <description>Testosterone levels changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dihydrotestosterone(DHT) levels changes over time</measure>
    <time_frame>day 7 and 14</time_frame>
    <description>Dihydrotestosterone(DHT) levels changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol levels changes over time</measure>
    <time_frame>day 7 and 14</time_frame>
    <description>Cholesterol levels changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin time (TT)</measure>
    <time_frame>day 7 and 14</time_frame>
    <description>Thrombin time (TT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days&#xD;
The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The standard therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>infected patients will receive the standard therapy for COVID-19 for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone</intervention_name>
    <description>The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days&#xD;
The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days</description>
    <arm_group_label>Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The standard therapy</intervention_name>
    <description>infected patients will receive the standard therapy for COVID-19 for 14 days</description>
    <arm_group_label>The standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult SARI patients with 2019-ncov infection confirmed by PCR; Absolute value of&#xD;
             lymphocytes &lt; 0. 6x 109/L; Severe respiratory failure within 48 hours and requires&#xD;
             admission to ICU. (severe respiratory failure was defined as PaO2/FiO2 &lt; 200 mmHg and&#xD;
             was supported by positive pressure mechanical ventilation (including non-invasive and&#xD;
             invasive mechanical ventilation, PEEP&gt;=5cmH2O))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Age &lt; 18 Pregnant Allergic to experimental drugs and patients have the following&#xD;
        conditions:&#xD;
&#xD;
          -  Hypercholesterolemia&#xD;
&#xD;
          -  Hypertriglyceridemia&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Sj√∂gren syndrome&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Depressive disorder&#xD;
&#xD;
          -  Body mass index less than 18 points or higher than 25 points&#xD;
&#xD;
          -  Contraindications for hormonal contraception or intrauterine device.&#xD;
&#xD;
          -  Autoimmune diseases A history of organ, bone marrow or hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Patients receiving anti-hcv treatment&#xD;
&#xD;
          -  Permanent blindness in one eye&#xD;
&#xD;
          -  History of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of&#xD;
             retinal detachment or eye surgery&#xD;
&#xD;
          -  Known malignant disease, PSA &gt; 3 ug/L, Nycturia &gt; 3 times&#xD;
&#xD;
          -  The competent physician considered it inappropriate to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mahmoud Elkazzaz, B.Sc in Biochemistry</last_name>
    <phone>00201090302015</phone>
    <email>mahmoudramadan2051@yahoo.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 8, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kafrelsheikh University</investigator_affiliation>
    <investigator_full_name>Mahmoud Ramadan mohamed Elkazzaz</investigator_full_name>
    <investigator_title>Faculty of Science, Damietta University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

